Liprolog Mix50

Insulin lispro, the active ingredient in Liprolog Mix50, is an insulin analog presented as a subcutaneous formulation for subcutaneous use. It lowers blood glucose levels and is used in the management of type 1 and type 2 diabetes mellitus.

GNH USA supplies Liprolog Mix50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable cold‑chain logistics. The company ensures product integrity through rigorous testing and regulatory compliance.

Insulin lispro is a rapid‑acting insulin analog used to control hyperglycemia in diabetes.

- Type 1 diabetes mellitus: provides mealtime insulin to match carbohydrate intake and reduce post‑prandial glucose spikes. - Type 2 diabetes mellitus: used as part of intensive insulin therapy to achieve glycemic targets when oral agents are insufficient. - Adjunct to basal insulin therapy: combined with long‑acting insulin to give flexible basal‑plus‑prandial coverage for patients needing both components.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Localized allergic reactions: mild rash or urticaria at the site.

Serious or Rare Side Effects: - Severe hypoglycemia: neuroglycopenic symptoms requiring immediate assistance. - Anaphylaxis: systemic allergic reaction with airway compromise. - Hypokalemia: low serum potassium levels. - Edema: peripheral swelling due to fluid retention. - Serum insulin antibodies: may alter insulin action. - Urticaria or angioedema: widespread hives or swelling.

Before using Liprolog Mix50, consider the following precautions. - Hypoglycemia risk: monitor blood glucose closely and adjust carbohydrate intake. - Dose adjustment: individualize dosing based on renal or hepatic function. - Concomitant medications: review other glucose‑lowering agents to avoid additive effects. - Allergic history: avoid if known hypersensitivity to insulin lispro or any excipients. - Pregnancy and lactation: assess benefit‑risk ratio with the prescriber. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro may interact with several drug classes.

Major Interactions (Avoid): - Concurrent sulfonylureas or meglitinides: increased risk of severe hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms and delay recovery. - Intravenous glucose infusion: can reduce insulin efficacy.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate insulin’s glucose‑lowering effect. - Thiazide diuretics: can raise blood glucose, requiring dose adjustments. - Oral contraceptives: may alter insulin requirements during hormonal changes.